Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/14428
Tipo de documento
ArtigoDireito Autoral
Acesso aberto
Coleções
- IOC - Artigos de Periódicos [12642]
Metadata
Mostrar registro completo
IN SILICO IDENTIFICATION AND VALIDATION OF A LINEAR AND NATURALLY IMMUNOGENIC B-CELL EPITOPE OF THE PLASMODIUM VIVAX MALARIA VACCINE CANDIDATE MEROZOITE SURFACE PROTEIN-9
Malária
Plasmodium vivax
Vacina
Proteína 9 de Superfície de Merozoito
Malaria
Vaccine
linear B cell epitope
Merozoite Surface Protein-9
Autor(es)
Afiliação
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunoparasitologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Grupo de Modelagem Computacional. Fortaleza, CE, Brasil.
Emory University. Yerkes National Primate Research Center. Emory Vaccine Center. Atlanta, GA, USA.
Emory University. Yerkes National Primate Research Center. Emory Vaccine Center. Atlanta, GA, USA.
Emory University. Environmental Health and Safety Office. Atlanta, GA, USA.
Fundação Nacional de Saúde. Departamento de Entomologia. Laboratório central. Porto Velho, RO, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório Referência Nacional de Simulídeos e Oncocercose. Rio de Janeiro, RJ, Brasil.
Emory University. Yerkes National Primate Research Center. Emory Vaccine Center. Atlanta, GA, USA / Emory University. Emory University School of Medicine. Department of Medicine. Division of Infectious Diseases. Atlanta, GA, USA.
Emory University. Yerkes National Primate Research Center. Emory Vaccine Center. Atlanta, GA, USA / Emory University. Emory University School of Medicine. Department of Medicine. Division of Infectious Diseases. Atlanta, GA, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunoparasitologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunoparasitologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Grupo de Modelagem Computacional. Fortaleza, CE, Brasil.
Emory University. Yerkes National Primate Research Center. Emory Vaccine Center. Atlanta, GA, USA.
Emory University. Yerkes National Primate Research Center. Emory Vaccine Center. Atlanta, GA, USA.
Emory University. Environmental Health and Safety Office. Atlanta, GA, USA.
Fundação Nacional de Saúde. Departamento de Entomologia. Laboratório central. Porto Velho, RO, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório Referência Nacional de Simulídeos e Oncocercose. Rio de Janeiro, RJ, Brasil.
Emory University. Yerkes National Primate Research Center. Emory Vaccine Center. Atlanta, GA, USA / Emory University. Emory University School of Medicine. Department of Medicine. Division of Infectious Diseases. Atlanta, GA, USA.
Emory University. Yerkes National Primate Research Center. Emory Vaccine Center. Atlanta, GA, USA / Emory University. Emory University School of Medicine. Department of Medicine. Division of Infectious Diseases. Atlanta, GA, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunoparasitologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunoparasitologia. Rio de Janeiro, RJ, Brasil.
Resumo em Inglês
Synthetic peptide vaccines provide the advantages of safety, stability and low cost. The
success of this approach is highly dependent on efficient epitope identification and synthetic
strategies for efficacious delivery. In malaria, the Merozoite Surface Protein-9 of Plasmodium
vivax (PvMSP9) has been considered a vaccine candidate based on the evidence that
specific antibodies were able to inhibit merozoite invasion and recombinant proteins were
highly immunogenic in mice and humans. However the identities of linear B-cell epitopes
within PvMSP9 as targets of functional antibodies remain undefined. We used several publicly-
available algorithms for in silico analyses and prediction of relevant B cell epitopes
within PMSP9.We show that the tandem repeat sequence EAAPENAEPVHENA
(PvMSP9E795-A808) present at the C-terminal region is a promising target for antibodies,
given its high combined score to be a linear epitope and located in a putative intrinsically
unstructured region of the native protein. To confirm the predictive value of the computational
approach, plasma samples from 545 naturally exposed individuals were screened for
IgG reactivity against the recombinant PvMSP9-RIRII729-972 and a synthetic peptide representing
the predicted B cell epitope PvMSP9E795-A808. 316 individuals (58%) were responders
to the full repetitive region PvMSP9-RIRII, of which 177 (56%) also presented total IgG
reactivity against the synthetic peptide, confirming it validity as a B cell epitope. The reactivity
indexes of anti-PvMSP9-RIRII and anti-PvMSP9E795-A808 antibodies were correlated.
Interestingly, a potential role in the acquisition of protective immunity was associated with the linear epitope, since the IgG1 subclass against PvMSP9E795-A808 was the prevalent subclass
and this directly correlated with time elapsed since the last malaria episode; however
this was not observed in the antibody responses against the full PvMSP9-RIRII. In conclusion,
our findings identified and experimentally confirmed the potential of PvMSP9E795-A808
as an immunogenic linear B cell epitope within the P. vivax malaria vaccine candidate
PvMSP9 and support its inclusion in future subunit vaccines.
Palavras-chave
Epitopo de célula linear BMalária
Plasmodium vivax
Vacina
Proteína 9 de Superfície de Merozoito
Palavras-chave em inglês
Plasmodium vivaxMalaria
Vaccine
linear B cell epitope
Merozoite Surface Protein-9
Compartilhar